Patricia Coyle from Stony Brook University: Moving Care of Progressive Multiple Sclerosis Forward

Video

As the treatment of relapsing remitting multiple sclerosis continues to add new treatment methods patients with progressive forms of the condition are still waiting for their first approved medication to manage their symptoms.

As the treatment of relapsing remitting multiple sclerosis continues to add new treatment methods patients with progressive forms of the condition are still waiting for their first approved medication to manage their symptoms.

Patricia K. Coyle, MD, from Stony Brook Medicine discussed developments made in the treatment of progressive forms of multiple sclerosis during the annual meeting of the Consortium of Multiple Sclerosis Centers. While the US Food and Drug Administration has not yet approved any treatments for the progressive form of the disease there are several drugs in the pipeline and one, Ocrelizumab, which is nearing the completion of the approval process.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.